ViiV Goes After Lupin Over HIV Drug ANDA
U.K.-based ViiV claims that a Lupin abbreviated new drug application infringes the patent covering Trizivir, an anti-retroviral treatment that uses three different types of drugs to better treat resistant strains of HIV.
“ViiV will be irreparably harmed by Lupin’s infringing activities unless those activities are enjoined by this court,” the complaint said. “ViiV does not have...
To view the full article, register now.